Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
A Agilent Technologies	$103.06 -2.0%	$122.01	$96.43 ▼ $155.35	$29.99B	1.19	1.85 million shs	1.33 million shs
HBIO Harvard Bioscience	$0.40 -0.2%	$0.78	$0.36 ▼ $4.42	$17.41M	1.47	192,562 shs	244,599 shs
PACB Pacific Biosciences of California	$1.27 -3.8%	$1.38	$1.08 ▼ $2.72	$378.27M	2.04	10.23 million shs	4.83 million shs
TMO Thermo Fisher Scientific	$440.91 -1.9%	$505.28	$409.85 ▼ $627.88	$169.62B	0.86	1.70 million shs	2.55 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
A Agilent Technologies	-2.03%	+4.13%	-15.20%	-27.52%	-26.50%
HBIO Harvard Bioscience	-0.20%	+7.89%	-39.03%	-80.05%	-91.10%
PACB Pacific Biosciences of California	-3.79%	+5.83%	+4.10%	-27.22%	-55.20%
TMO Thermo Fisher Scientific	-1.71%	+5.59%	-15.77%	-20.07%	-20.96%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
A Agilent Technologies	4.5021 of 5 stars	3.2	5.0	1.7	3.6	3.5	0.8	1.3
HBIO Harvard Bioscience	3.6707 of 5 stars	3.3	3.0	0.0	4.5	1.1	1.7	0.6
PACB Pacific Biosciences of California	2.6396 of 5 stars	4.3	1.0	0.0	0.0	2.4	0.8	1.3
TMO Thermo Fisher Scientific	4.9345 of 5 stars	4.4	5.0	1.7	4.1	4.0	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
A Agilent Technologies	2.46	Hold	$146.25	41.91% Upside
HBIO Harvard Bioscience	2.50	Moderate Buy	$4.50	1,039.24% Upside
PACB Pacific Biosciences of California	2.54	Moderate Buy	$2.46	93.57% Upside
TMO Thermo Fisher Scientific	2.81	Moderate Buy	$647.43	46.84% Upside

Current Analyst Ratings Breakdown

Latest PACB, HBIO, TMO, and A Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/10/2025	A Agilent Technologies	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy	$135.00
4/10/2025	A Agilent Technologies	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$138.00 ➝ $115.00
4/10/2025	PACB Pacific Biosciences of California	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $3.00
4/10/2025	TMO Thermo Fisher Scientific	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$620.00 ➝ $475.00
4/9/2025	HBIO Harvard Bioscience	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Sector Weight
3/25/2025	PACB Pacific Biosciences of California	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$6.00 ➝ $2.00
3/24/2025	HBIO Harvard Bioscience	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Speculative Buy ➝ Speculative Buy	$5.50 ➝ $4.50
3/4/2025	TMO Thermo Fisher Scientific	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$650.00 ➝ $570.00
2/27/2025	A Agilent Technologies	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$161.00 ➝ $159.00
2/20/2025	PACB Pacific Biosciences of California	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$2.50 ➝ $2.00
2/18/2025	PACB Pacific Biosciences of California	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$1.75 ➝ $1.50

(Data available from 4/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
A Agilent Technologies	$6.51B	4.51	$6.12 per share	16.83	$20.53 per share	5.02
HBIO Harvard Bioscience	$94.14M	0.18	$0.08 per share	5.16	$1.71 per share	0.23
PACB Pacific Biosciences of California	$154.01M	2.46	N/A	N/A	$2.62 per share	0.48
TMO Thermo Fisher Scientific	$42.88B	3.88	$24.62 per share	17.91	$129.54 per share	3.40

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
A Agilent Technologies	$1.29B	$4.35	23.69	17.01	2.96	19.27%	25.56%	13.47%	5/27/2025 (Estimated)
HBIO Harvard Bioscience	-$3.41M	-$0.29	N/A	∞	N/A	-14.57%	-4.64%	-2.40%	5/6/2025 (Estimated)
PACB Pacific Biosciences of California	-$308.65M	-$1.64	N/A	N/A	N/A	-200.40%	-42.89%	-14.77%	5/8/2025 (Estimated)
TMO Thermo Fisher Scientific	$6.34B	$16.53	26.67	17.25	2.99	14.78%	17.51%	8.52%	4/23/2025 (Estimated)

Latest PACB, HBIO, TMO, and A Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	PACB Pacific Biosciences of California	-$0.19	N/A	N/A	N/A	$36.90 million	N/A
5/6/2025	Q1 2025	HBIO Harvard Bioscience	-$0.0350	N/A	N/A	N/A	$19.70 million	N/A
4/23/2025	Q1 2025	TMO Thermo Fisher Scientific	$5.11	N/A	N/A	N/A	$10.23 billion	N/A
2/26/2025	Q1 2025	A Agilent Technologies	$1.27	$1.31	+$0.04	$1.11	$1.67 billion	$1.68 billion
2/13/2025	Q4 2024	PACB Pacific Biosciences of California	-$0.20	-$0.20	N/A	-$0.49	$39.20 million	$39.22 million
1/30/2025	Q4 2024	TMO Thermo Fisher Scientific	$5.94	$6.10	+$0.16	$4.78	$11.29 billion	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
A Agilent Technologies	$0.99	0.96%	+6.47%	22.76%	N/A
HBIO Harvard Bioscience	N/A	N/A	N/A	N/A	N/A
PACB Pacific Biosciences of California	N/A	N/A	N/A	N/A	N/A
TMO Thermo Fisher Scientific	$1.72	0.39%	+14.47%	10.41%	N/A

Latest PACB, HBIO, TMO, and A Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/19/2025	A Agilent Technologies	quarterly	$0.2480	0.72%	4/1/2025	4/1/2025	4/23/2025
2/19/2025	TMO Thermo Fisher Scientific	quarterly	$0.43	0.32%	3/14/2025	3/14/2025	4/15/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
A Agilent Technologies	0.56	2.20	1.66
HBIO Harvard Bioscience	0.52	2.06	0.91
PACB Pacific Biosciences of California	1.97	9.74	8.64
TMO Thermo Fisher Scientific	0.59	1.66	1.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
A Agilent Technologies	N/A
HBIO Harvard Bioscience	80.87%
PACB Pacific Biosciences of California	N/A
TMO Thermo Fisher Scientific	89.23%

Insider Ownership

Company	Insider Ownership
A Agilent Technologies	N/A
HBIO Harvard Bioscience	9.00%
PACB Pacific Biosciences of California	2.40%
TMO Thermo Fisher Scientific	0.34%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
A Agilent Technologies	17,900	285.10 million	N/A	Optionable
HBIO Harvard Bioscience	490	44.07 million	39.69 million	Optionable
PACB Pacific Biosciences of California	730	297.85 million	267.29 million	Optionable
TMO Thermo Fisher Scientific	130,000	377.49 million	381.20 million	Optionable

PACB, HBIO, TMO, and A Headlines

Recent News About These Companies

Granite Investment Partners LLC Reduces Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

April 16 at 5:23 AM | marketbeat.com

Sagespring Wealth Partners LLC Makes New Investment in Thermo Fisher Scientific Inc. (NYSE:TMO)

April 16 at 5:22 AM | marketbeat.com

Thermo Fisher Scientific (TMO) Projected to Post Earnings on Wednesday

April 16 at 2:07 AM | americanbankingnews.com

Thermo Fisher Scientific Stock Up 1.3% After Key Signal

April 15 at 6:55 PM | benzinga.com

Menora Mivtachim Holdings LTD. Has $114.09 Million Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

April 15 at 8:57 AM | marketbeat.com

Advisors Capital Management LLC Acquires 3,462 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

April 15 at 7:08 AM | marketbeat.com

Sterling Capital Management LLC Cuts Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

April 15 at 6:29 AM | marketbeat.com

Thermo Fisher Scientific Inc. (NYSE:TMO) Receives $647.43 Consensus Price Target from Analysts

April 15 at 2:01 AM | americanbankingnews.com

Thermo Fisher price target lowered to $545 from $680 at BofA

April 14 at 6:58 PM | markets.businessinsider.com

Thermo Fisher Scientific Introduces 5L DynaDrive Single-Use Bioreactor

April 14 at 1:57 PM | contractpharma.com

Thermo Fisher Scientific (NYSE:TMO) Launches 5L DynaDrive Bioreactor To Enhance Bioprocessing

April 14 at 1:57 PM | finance.yahoo.com

Thermo Fisher Scientific And Its Real Value

April 14 at 12:09 PM | seekingalpha.com

Thermo Fisher Scientific And Its Real Value

April 14 at 12:03 PM | seekingalpha.com

Townsquare Capital LLC Cuts Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

April 14 at 7:54 AM | marketbeat.com

Rockefeller Capital Management L.P. Boosts Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

April 14 at 6:34 AM | marketbeat.com

Heritage Trust Co Buys Shares of 1,176 Thermo Fisher Scientific Inc. (NYSE:TMO)

April 14 at 6:16 AM | marketbeat.com

CenterBook Partners LP Grows Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

April 14 at 5:30 AM | marketbeat.com

Trexquant Investment LP Sells 23,708 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

April 14 at 4:04 AM | marketbeat.com

Thermo Fisher Scientific Inc. (NYSE:TMO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

April 14 at 1:30 AM | marketbeat.com

Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Titan Global Capital Management USA LLC

April 13 at 8:10 AM | marketbeat.com

Coign Capital Advisors LLC Takes Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

April 13 at 8:01 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NVIDIA Insiders Sell: This Is What It Means for the Market
By Thomas Hughes | March 25, 2025
View NVIDIA Insiders Sell: This Is What It Means for the Market
5 Reasons the S&P 500 Could Rebound Strongly in 2025
By Thomas Hughes | April 3, 2025
View 5 Reasons the S&P 500 Could Rebound Strongly in 2025
Analysts Stay Bullish on Rocket Lab as Signs of a Bottom Emerge
By Ryan Hasson | March 21, 2025
View Analysts Stay Bullish on Rocket Lab as Signs of a Bottom Emerge
Palantir Setting Up to Be a Big Winner With New Defense Spending
By Chris Markoch | March 26, 2025
View Palantir Setting Up to Be a Big Winner With New Defense Spending
3 Dividend Stocks Offering Higher Yields and Bullish Forecasts
By Sarah Horvath | March 17, 2025
View 3 Dividend Stocks Offering Higher Yields and Bullish Forecasts

PACB, HBIO, TMO, and A Company Descriptions

Agilent Technologies NYSE:A

$103.06 -2.13 (-2.03%)

Closing price 04/15/2025 03:59 PM Eastern

Extended Trading

$101.56 -1.50 (-1.46%)

As of 04:41 AM Eastern

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment focuses on genomics, nucleic acid contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership, and biomolecular analysis businesses. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and offers services portfolio, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, and consulting services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.

Harvard Bioscience NASDAQ:HBIO

$0.40 0.00 (-0.20%)

Closing price 04/15/2025 04:00 PM Eastern

Extended Trading

$0.42 +0.02 (+6.08%)

As of 04:21 AM Eastern

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

Pacific Biosciences of California NASDAQ:PACB

$1.27 -0.05 (-3.79%)

Closing price 04/15/2025 04:00 PM Eastern

Extended Trading

$1.27 +0.00 (+0.39%)

As of 05:51 AM Eastern

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Thermo Fisher Scientific NYSE:TMO

$440.91 -8.42 (-1.87%)

Closing price 04/15/2025 03:59 PM Eastern

Extended Trading

$440.21 -0.70 (-0.16%)

As of 06:17 AM Eastern

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time